NCT00565539 - Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Hepatitis C, Chronic

Interventions

DRUG

PEGylated recombinant interleukin 29 (PEG-rIL-29)

subcutaneous administration either weekly or every other week

Trial Locations (11)

VCUHS Hepatology Research Division, Richmond

Duke University Medical Center, Durham

Henry Ford Health System, Detroit

Mayo Clinic, Rochester

Northwestern Memorial Hospital, Chicago

Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston

St. Luke's Advanced Liver Therapies, Houston

Alamo Medical Research, San Antonio

Oregon Health Sciences University, Portland

University Hospital (UMDNJ), Newark

London Health Sciences Center, London